Biosimilar Testing and Development Services Market to Reach $7.8 Billion by 2032

Biosimilar Testing and Development Services Market

The global biosimilar testing and development services market was valued at $2.5 billion in 2022 and is projected to grow to $7.8 billion by 2032, expanding at a CAGR of 12.1% from 2023 to 2032. This significant growth is driven by the rising demand for affordable biologics, increased chronic disease prevalence, and the upcoming patent cliffs of blockbuster biologic drugs.


Why Biosimilar Testing and Development Services Matter

Biosimilars are near-identical copies of approved biologic drugs, offering similar efficacy and safety but at a lower cost. However, due to the complexity of biologics, biosimilars require rigorous testing and validation before approval.

Key components of biosimilar testing include:

  • Pharmacokinetics (PK) Studies: Evaluate absorption, distribution, metabolism, and excretion.

  • Immunogenicity Testing: Assess the potential for immune response or adverse effects.

  • Analytical & Comparability Testing: Ensure biosimilars mirror reference products in structure and function.


Key Market Growth Drivers

Several macro trends and industry dynamics are propelling the expansion of this market:

✅ 1. Rising Demand for Affordable Biosimilars

  • Biologic drugs are high-cost treatments, often limiting access.

  • Biosimilars offer a cost-effective alternative with comparable therapeutic benefits.

  • Healthcare systems are actively adopting biosimilars to reduce treatment costs and improve accessibility.

✅ 2. Surge in Chronic Diseases

Chronic conditions requiring long-term biologic therapies are on the rise:

  • Cancer: 1.9 million new cases in the U.S. in 2023 (American Cancer Society).

  • Diabetes: Affects 537 million adults globally (International Diabetes Federation).

  • Autoimmune Diseases: Including rheumatoid arthritis, Crohn’s disease, and lupus, where biologics play a critical role.

✅ 3. Patent Expiration of Major Biologics

Several high-revenue biologics are nearing patent expiration, creating opportunities for biosimilar development:

  • Keytruda (expires 2028)

  • Eylea (expires 2025–2026)

  • Stelara (expires 2025–2026)

✅ 4. Rise of Outsourcing to CROs

Pharma and biotech companies are increasingly outsourcing biosimilar testing to Contract Research Organizations (CROs) to reduce R&D costs and accelerate timelines.


Market Challenges

Despite promising growth, the industry faces key challenges:

⚠️ 1. Stringent Regulatory Requirements

Regulatory agencies like the FDA (U.S.) and EMA (Europe) impose complex approval processes, requiring:

  • Extensive preclinical and clinical testing

  • Demonstration of biosimilarity in multiple parameters

  • Post-marketing surveillance

⚠️ 2. Economic Pressures and Budget Cuts

The global economic downturn in 2023 led to reduced R&D budgets across the pharma sector, temporarily impacting biosimilar investment and development timelines.


Market Segmentation: Detailed Insights

1. By Type of Testing

  • Pharmacokinetics (PK) Testing: Held the largest share in 2022, critical for regulatory approval.

  • Immunogenicity Testing: Projected to be the fastest-growing segment, given the importance of minimizing immune-related risks.

2. By End User

  • Pharmaceutical & Biopharmaceutical Companies: Dominated in 2022 due to in-house development programs.

  • Contract Research Organizations (CROs): Poised for the highest growth as outsourcing gains traction.

3. By Region

  • North America: Largest market share in 2022, driven by early biosimilar adoption, strong regulatory frameworks, and innovation.

  • Asia-Pacific: Fastest-growing region due to:

    • Government support

    • Cost-effective manufacturing

    • Increased clinical trial activity


Competitive Landscape

Key players driving innovation and service expansion in the biosimilar testing space include:

  • Charles River Laboratories

  • Sartorius AG

  • Eurofins Scientific SE

  • SGS

  • Intertek Group plc

Recent Developments

  • Eurofins Scientific SE (Jan 2023): Opened a new bioanalytical and toxicology lab in Hyderabad, India, enhancing global testing capabilities.

  • Pacific Biolabs, Inc. (May 2022): Expanded in vitro testing services to support pharmaceutical and biotech clients.


Future Outlook: 2024–2032

The next decade presents a strong growth trajectory for the biosimilar testing and development market, supported by:

✔ Increased global biosimilar approvals
✔ Government initiatives supporting affordable healthcare
✔ Technological advancements in analytical tools, automation, and AI-driven testing platforms


Key Takeaways for Investors and Stakeholders

📌 Asia-Pacific is the region to watch – Offering low-cost manufacturing, increasing clinical trial activity, and strong government backing.

📌 Immunogenicity testing is a hot spot – As regulatory agencies emphasize patient safety, this segment will see rapid adoption.

📌 Strategic collaborations are crucial – M&A, partnerships, and technology integration will differentiate market leaders from laggards.


Final Thoughts

The biosimilar testing and development services market is entering a golden era. As demand for cost-effective biologics surges and regulatory paths become clearer, the market will offer significant returns for pharma companies, CROs, and biotech investors.

Despite regulatory hurdles and economic uncertainties, the long-term potential remains robust—making this sector one of the most lucrative and impactful areas in the global healthcare ecosystem.

Allied Market Research

Allied Market Research

Allied Market Research (AMR) is approved by the Newstrail editorial board to share timely, data-driven insights. As a trusted leader in market research and analysis across multiple industries, AMR delivers in-depth reports and expert commentary to help businesses stay ahead of emerging trends.